Eric Singhi/X
Mar 26, 2025, 18:16
Eric K. Singhi: Breaking news – the Overall Survival results from MARIPOSA are out at ELCC25
Eric K. Singhi, Assistant Professor at MD Anderson Cancer Center, shared his post on X, adding:
“Breaking news – the Overall Survival results from MARIPOSA are out at ELCC25.
Does this update change practice for all patients with treatment-naïve EGFR+ metastatic NSCLC?
Let’s dive into the details
MARIPOSA OS data is here – what now while we await FLAURA2 OS data?
- Ami + Laz should be part of clinic discussions.
- Managing toxicity is key. Supportive efforts are a must.
- Shared decision-making matters.
Jill Feldman, eager for your thoughts!
Access to slides and presentation can be found here.
Quoting his earlier post:
“MARIPOSA study update: Combination therapy shows over ONE-YEAR mOS improvement compared to osimertinib alone.
Key data to discuss with patients in clinic – but does this simplify first-line treatment decisions?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 18:52
Mar 30, 2025, 18:31